title: [Treatment of lymphangioma with OK-432 infiltration].
abstract: The management of lymphangioma using sclerotherapy has proven to be an effective therapeutic. Our aim was to evaluate the therapeutic efficacy of OK-432 (Picibanil) in patients with lymphagioma.
  
  
  METHODS
  The study was performed from November 2010 to July 2011. Fifteen patients of both genders were diagnosed with lymphangioma, 12 days to 12 years old. All patients were infiltrated with OK-432. The studied variables were: previous surgery, localization, type of lymphangioma, number of effective injections, reduction of mass valued as excellent (100% reduction), good (reduction > 50%) and bad (reduction < 50%), presence of recurrence and complications.
  
  
  RESULTS
  40% of pacients had prior surgery and 53.3% were located in the cervical-face region. The type of macrocystic lymphangioma was present in 40% of the series, mixed type in 46.6% and microcystic type in 13.4%. The number of effective infiltrations were 3. In 6 cases (40%) the result was excellent in 5 cases (33.4%) the result was good and in 4 cases (26.6%). We had 1 recurrence (6.6%) and we haven't had complications.
  
  
  CONCLUSIONS
  Injection of OK-432 in macrocystic lymphangioma and mixed had a safe therapeutic modality with satisfactory results. So it is a valid alternative to conventional surgery.
authors: Servicio de Cirugía Pediátrica, Hospital Pediátrico Baca Ortiz, Quito-Ecuador.
authors: J
authors: J
authors: Rodríguez
authors: F
authors: F
authors: Cáceres
authors: P
authors: P
authors: Vargas
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D036502:Infusions, Intralesional; D008202:Lymphangioma / Q000188:drug therapy*; D008297:Male; D010844:Picibanil / Q000008:administration & dosage*; D011446:Prospective Studies
chemical_list: D000970:Antineoplastic Agents; D010844:Picibanil